Dexcom (DXCM) Cash from Operations Growth (3y) (2013 - 2026)
Dexcom (DXCM) Cash from Operations Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 198.90 Bn | 193.29 Bn | 7.27 Bn | 27.41% |
| 2 | Stryker | 129.12 Bn | 125.64 Bn | 4.50 Bn | 22.38% |
| 3 | Medtronic | 119.32 Bn | 110.10 Bn | 6.41 Bn | 1.51% |
| 4 | Boston Scientific | 73.63 Bn | 73.09 Bn | 3.85 Bn | 30.85% |
| 5 | Edwards Lifesciences | 52.14 Bn | 47.89 Bn | 1.35 Bn | 168.71% |
| 6 | Dexcom | 34.48 Bn | 32.54 Bn | 830.00 Mn | 12.26% |
| 7 | GE HealthCare Technologies | 34.06 Bn | 31.95 Bn | 2.18 Bn | 65.19% |
| 8 | Koninklijke Philips | 26.40 Bn | 23.08 Bn | 4.55 Bn | 43.79% |
| 9 | Steris | 23.17 Bn | 22.69 Bn | 684.20 Mn | 9.30% |
| 10 | Zimmer Biomet Holdings | 19.34 Bn | 18.93 Bn | 1.54 Bn | 8.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.26% |
| Mar 31, 2026 | 50.11% |
| Dec 31, 2025 | 30.43% |
| Sep 30, 2025 | 31.05% |
| Jun 30, 2025 | 20.59% |
| Mar 31, 2025 | 37.31% |
| Dec 31, 2024 | 41.76% |
| Sep 30, 2024 | -6.91% |
| Jun 30, 2024 | 65.53% |
| Mar 31, 2024 | 95.96% |
| Dec 31, 2023 | -8.08% |
| Sep 30, 2023 | 22.18% |
| Jun 30, 2023 | 7.29% |
| Mar 31, 2023 | 334.08% |
| Dec 31, 2022 | -2.67% |
| Sep 30, 2022 | 45.85% |
| Jun 30, 2022 | 38.89% |
| Mar 31, 2022 | 81.88% |
| Dec 31, 2021 | 46.43% |
| Sep 30, 2021 | 63.29% |